The SAFER study, the world’s largest randomized trial of atrial fibrillation screening, has now completed its screening phase, where participants were screened using Zenicor One […]
Zenicor Medical Systems AB has signed an agreement with two university hospitals in Northamptonshire, UK, for the delivery of the Zenicor Solution with Zenicor One […]
In 2024, two thousand people in Värmland will be screened for atrial fibrillation with the Zenicor One for early detection and reduced risk of suffering […]
Stockholm 16 November 2023 People from over a hundred health centers in England are being screened for atrial fibrillation at a high rate with Zenicor […]
Stockholm 14 November 2023 The health-economic results of the large Swedish screening study STROKETOP, in which the Zenicor solution has been used to screen for […]
Stockholm 9 May 2023 Today, the Non-Governmental patient organization The Swedish Heart and Lung Association published a report on Atrial Fibrillation “Flimmerrapporten 2023”. The report […]
Stockholm 20 January 2023 As one of the first Swedish SME companies, Zenicor has been certified according to the new EU Medical Device Regulation (MDR). […]
Stockholm 30 March 2023 Zenicor has today been awarded SEK 2.7 million by Sweden’s innovation agency Vinnova through the Swelife and Medtech4Health program “Collaborative project […]
Feasibility of screening for atrial fibrillation in a domiciliary setting: opportunistic one-time screening at preventive home visits in municipalities Poulsen P-B. , Hemmingsen U., Melgaard […]
During the European Digital Heart Congress ESC, the health economic results from the STROKESTOP study were presented for the first time. The study where the […]
